What changed in this filing

/stocks — the workspaceLOADING

Item 1. Financial Statements

2022-11-30 compared with 2022-11-30 · 338 added, 353 removed, 472 unchanged (59% of the section changed)

2 unchanged sentences

CONDENSED BALANCE SHEETS

September 30,

CURRENT ASSETS:

1 unchanged sentence

Other prepaid expenses and deposit

Notes Receivables to Acquisition in progress

Total Current Assets

2 unchanged sentences

Investment in Avra Air LLC

OTHER ASSETS:

Accumulated amortization

11 unchanged sentences

Preferred stock, 5,000,000 shares authorized, $.0001 par value par value, none issued or outstanding

Common stock, 100,000,000 shares authorized, $ .0001 par value, 40,832,322 and 37,848,905 issued and outstanding at September 30, 2022 and December 31, 2021 respectively

Common stock liability, 4,325,639 and 4,265,295 shares, $.0001 par value at September 30, 2022 and December 31, 2021, respectively

Common stock, 100,000,000 shares authorized, $ .0001 par value, 38,089,675 and 37,849,405 issued and outstanding at March 31, 2022 and December 31, 2021 respectively

Common stock liability, 4,857,476 and 42,65,295 shares, $ .0001 par value at March 31, 2022 and December 31, 2021, respectively

Additional paid-in capital

9 unchanged sentences

For The Three Months

For the Nine Months

Ended September 30,

For The Six Months

Ended June 30,

OPERATING EXPENSES:

5 unchanged sentences

Interest Earned

Fees & Charges

Interest Expense

Total Other Income and (Expenses), net

Loss before Income Taxes

( 1,040,525 )

( 1,130,578 )

Provision for Income Taxes

7 unchanged sentences

AVRA MEDICAL ROBOTICS, INC.

CONDENSED STATEMENT OF STOCKHOLDERS’ DEFICIT

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER

30, 2022 AND 2021

Stockholders’

CONDENSED STATEMENT OF

STOCKHOLDERS’ (DEFICIT)

FOR THE SIX MONTHS ENDED

JUNE 30, 2022 AND 2021

Total Stockholders’

BALANCE AT DECEMBER 31, 2021

4 unchanged sentences

Security offerings

Treasury stock

Common stock issuable for services

3 unchanged sentences

Stock based compensation expense

Conversion of debt to equity

Stock issued for services

Secuity offerings

Common stock issuable for services

Common stock issued

$ ( 170,001 )

BALANCE AS AT JUNE 30, 2022

$ ( 8,754,482 )

Stock based compensation expense

Security offerings

Common stock issuable for services

Conversion of debt to equity

Treasury Stock

Common stock issued

$ ( 170,001 )

$ ( 790,104 )

BALANCE AS AT SEPTEMBER 30, 2022

BALANCE AT JUNE 30, 2022

$ ( 8,754,481 )

3 unchanged sentences

Stock based compensation expense

Conversion of debt to equity

Stock issued for services

Security offerings

Security offering

Common stock issuable for services

Common stock issued

$ ( 300,056 )

BALANCE AT MARCH 31, 2021

3 unchanged sentences

Stock issued for services

Secuity offerings

Common stock issuable for services

Security offering

Common stock issued

$ ( 412,314 )

BALANCE AS AT JUNE 30, 2021

1 unchanged sentence

$ ( 857,933 )

Stock based compensation expense

Common stock issuable for services

Conversion of debt to equity

$ ( 418,209 )

BALANCE AS AT SEPTEMBER 30, 2021

$ ( 8,124,325 )

$ ( 941,496 )

See accompanying notes to unaudited Condensed

Financial Statements.

AVRA MEDICAL ROBOTICS, INC.

See accompanying notes to unaudited Condensed Financial

ROBOTICS, INC.

CONDENSED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30,

FOR THE SIX MONTHS ENDED JUNE 30,

CASH FLOWS FROM OPERATING ACTIVITIES:

1 unchanged sentence

$ ( 712,370 )

Adjustments to reconcile net loss to net cash used in operating activities:

Adjustments to reconcile net loss to net cash used in

operating activities:

Depreciation and amortization expense

Stock compensation expense

Stock issued for services

Non-cash interest

Investment loss

Changes in operating assets and liabilities:

Prepaid expenses

Accounts payable, notes payable and accrued expenses

Accounts payable and accrued expenses

Net Cash Used in Operating Activities

INVESTING ACTIVITIES:

Notes receivable

( 1,100,000 )

Equipment acquisition

Investment in Avra Air LLC

Net Cash Used in Investing Activities

( 1,100,000 )

FINANCING ACTIVITIES:

Proceeds from exercise of stock options

Proceeds from private placement

Proceeds from securities offering

Proceeds from related party

Proceeds from promissory notes

Proceeds from SBA

Proceeds from securities offering

Net Cash Provided by Financing Activities

7 unchanged sentences

Non-cash financing activities:

Equipment acquisition included in accounts payable

Related party note payable converted into common stock

3 unchanged sentences

AVRA MEDICAL ROBOTICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

NOTES TO FINANCIAL STATEMENTS

NOTE 1 – COMPANY AND BASIS OF PRESENTATION

9 unchanged sentences

implantable devices and surgical robotic training.

The significant accounting policies of AVRA were

described in Note 1 to the audited financial statements included in the Company’s 2021 Annual Report on Form 10-K (“2021 Form

There have been no significant changes in the Company’s significant accounting policies for the three and nine months

ended September 30, 2022.

The significant accounting

policies of AVRA were described in Note 1 to the audited financial statements included in the Company’s 2021 Annual Report on Form

10-K (“2021 Form 10-K”).

There have been no significant changes in the Company’s significant accounting policies for

the three and six months ended June 30, 2022.

Basis of Presentation

The accompanying unaudited condensed financial

statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States (“GAAP”)

for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission.

they do not include all information and footnotes normally included in annual consolidated financial statements and should be read in

conjunction with the consolidated financial statements and notes thereto included in the 2021 Form 10-K for the year ended December 31,

In the opinion of the Company’s management, the accompanying unaudited condensed financial statements contain all the adjustments

necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of September 30, 2022, and

the results of operations and cash flows for the periods presented.

The results of operations for the three and nine months ended September

30, 2022, are not necessarily indicative of the operating results for the full fiscal year or any future period.

The accompanying unaudited

condensed financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United

States (“GAAP”) for interim financial information and in accordance with the rules and regulations of the Securities and Exchange

Therefore, they do not include all information and footnotes normally included in annual consolidated financial statements

and should be read in conjunction with the consolidated financial statements and notes thereto included in the 2021 Form 10-K for the

year ended December 31, 2021.

In the opinion of the Company’s management, the accompanying unaudited condensed financial statements

contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company

as of June 30, 2022 and the results of operations and cash flows for the periods presented.

The results of operations for the three and

six months ended June 30, 2022 are not necessarily indicative of the operating results for the full fiscal year or any future period.

Going Concern

1 unchanged sentence

prepared assuming the continuation of the Company as a going concern.

At September 30, 2022, the Company’s stockholders’ deficit

At June 30, 2022, the Company’s stockholders’ deficit

was $ 59,653 which raises substantial doubt about the Company.

1 unchanged sentence

to cover its operating costs and is dependent on debt and equity financing to fund its operations.

The management of the Company is making

Management of the Company is making

efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect.

24 unchanged sentences

Revenue Recognition

In May 2014, the Financial Accounting Standards

Board (“FASB”) issued Accounting Standards Update (“ASU”) No.

2014-09, Revenue from Contracts with Customers (Topic

The ASU and all subsequently issued clarifying ASUs replaced most existing revenue recognition guidance in U.S.

required expanded disclosures relating to the nature amount, timing, and uncertainty of revenue and cash flows arising from contracts

with customers.

The Company adopted the new standard effective January 1, 2018, the first day of the Company’s fiscal year.

these reasons, the adoption of this ASU did not have a significant impact on the Company’s financial statements

Effective January 1, 2018, the Company adopted

guidance issued by the FASB regarding recognizing revenue from contracts with customers.

The revenue recognition policies as enumerated

below reflect the Company’s accounting policies effective January 1, 2018, which did not have a materially different financial statement

result than what the results would have been under the previous accounting policies for revenue recognition.

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No.

2014-09, Revenue

from Contracts with Customers (Topic 606).

The ASU and all subsequently issued clarifying ASUs replaced most existing revenue recognition

guidance in U.S.

The ASU also required expanded disclosures relating to the nature amount, timing, and uncertainty of revenue and

cash flows arising from contracts with customers.

The Company adopted the new standard effective January 1, 2018, the first day of the

Company’s fiscal year.

For these reasons, the adoption of this ASU did not have a significant impact on the Company’s financial

January 1, 2018, the Company adopted guidance issued by the FASB regarding recognizing revenue from contracts with customers.

recognition policies as enumerated below reflect the Company’s accounting policies effective January 1, 2018, which did not have

a materially different financial statement result than what the results would have been under the previous accounting policies for revenue

Equipment is recorded at cost and depreciated

2 unchanged sentences

is as follows:

Equipment - 5 years straight-line

Intangible assets continue to be subject to amortization,

and any impairment is determined in accordance with ASC 360, “Property, Plant, and Equipment,” intangible assets are stated

at historical cost and amortized over their estimated useful lives.

The Company uses a straight-line method of amortization, unless a

method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be

reliably determined

The Company purchased existing Intellectual Property

from the University of Central Florida.

Management regularly assesses the carrying value of the intellectual property to determine if

there has been any diminution of value.

Equipment - 5 years

straight-line

assets continue to be subject to amortization, and any impairment is determined in accordance with ASC 360, “Property, Plant, and

Equipment,” intangible assets are stated at historical cost and amortized over their estimated useful lives.

The Company uses a

straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible

asset are consumed or otherwise used up can be reliably determined

purchased existing Intellectual Property from the University of Central Florida.

Management regularly assesses the carrying value of the

intellectual property to determine if there has been any diminution of value.

Website is recorded at cost and amortized using

46 unchanged sentences

In accordance with ASC Topic 730 “Research

and Development”, with the exception of intellectual property that is purchased from another enterprise and have alternative future

use, research and development expenses are charged to operations as incurred.

and Development”, with the exception of intellectual property that is purchased from another

enterprise and have alternative future use, research and development expenses are charged to operations as incurred.

Fair Value of Financial Instruments

13 unchanged sentences

statements or the related disclosures.

In February 2016, the FASB issued ASU 2016-02,

“Leases (Topic 842)” (“ASU 2016-02”).

The FASB issued ASU 2016-02 to increase transparency and comparability among

organizations recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements.

Under ASU 2016-02, lessors will account for leases using an approach that is substantially equivalent to existing GAAP for sales-type

leases, direct financing leases and operating leases.

Unlike current guidance, however, a lease with collectability uncertainties may

be classified as a sales-type lease.

If collectability of lease payments, plus any amount necessary to satisfy a lessee residual value

guarantee, is not probable, lease payments received will be recognized as a deposit liability and the underlying assets will not be derecognized

until collectability of the remaining amounts becomes probable.

ASU 2016-02 is effective for interim and annual periods beginning after

December 15, 2018, with early adoption permitted, and must be adopted using a modified retrospective transition.

The Company did not adopt

the standard effective January 1, 2019, utilizing the lessor practical expedient.

On November 15, 2019, the FASB issued ASU 2019-10

which amended the effective dates for ASC 842, to give implementation relief.

Under the FASB’s new framework, two “buckets”

were defined, bucket 1 includes public companies that are SEC filers but excludes “Small Reporting Companies” (SRC’s).

2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”).

The FASB issued ASU 2016-02 to increase

transparency and comparability among organizations recognizing lease assets and lease liabilities on the balance sheet and disclosing

key information about leasing arrangements.

Under ASU 2016-02, lessors will account for leases using an approach that is substantially

equivalent to existing GAAP for sales-type leases, direct financing leases and operating leases.

Unlike current guidance, however, a lease

with collectability uncertainties may be classified as a sales-type lease.

If collectability of lease payments, plus any amount necessary

to satisfy a lessee residual value guarantee, is not probable, lease payments received will be recognized as a deposit liability and the

underlying assets will not be derecognized until collectability of the remaining amounts becomes probable.

ASU 2016-02 is effective for

interim and annual periods beginning after December 15, 2018, with early adoption permitted, and must be adopted using a modified retrospective

The Company did not adopt the standard effective January 1, 2019, utilizing the lessor practical expedient.

15, 2019, the FASB issued ASU 2019-10 which amended the effective dates for ASC 842, to give implementation relief.

Under the FASB’s

new framework, two “buckets” were defined, bucket 1 includes public companies that are SEC filers but excludes “Small

Reporting Companies” (SRC’s).

Bucket 2 includes all other entities, including SRC’s.

Bucket 2 entities have to apply ASC 842 for fiscal years beginning after

December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022.

Bucket 2 entities have to apply

ASC 842 for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021.

NOTE 3 – NOTES PAYABLE – RELATED PARTY

18 unchanged sentences

to December 31, 2020.

March 1, 2020, the Company entered into a promissory note totaling $ 194,500 for the above notes, as an incentive to its CEO for

March 1, 2020, the Company entered into a promissory notes totaling $ 194,500 for the above notes, as an incentive to its CEO for

entering into this agreement, issued option to purchase 389,000 restricted common shares of the Company at $ 0.25 per share.

18 unchanged sentences

Company borrowed from its CEO, $ 5,000 under a non-interest bearing promissory note which matures on December 31, 2020 .

On September 22, 2021, the Company’s CEO,

converted a total of $ 50,000 of notes payable into 384,615 shares of common stock and converted $ 50,000 of accrued salary into 384,615

shares of common stock.

NOTE 4 – PROMISSORY NOTES

17 unchanged sentences

This note was paid in full on January 21, 2020.

During the three and six months ended June 30,

2020, 37,500 warrants were valued at $ 51,740 and expensed as stock compensation.

On August 5, 2022, AVRA entered into a non-binding

letter of intent with Dr.

Sudhir Srivastava (“ Dr.

Sudhir ”), Cardio Ventures Pvt.

Ltd., a Bahamian private limited company

Sudhir is the sole stockholder(“ Cardio ”), Otto Pvt, Ltd., a Bahamian private limited company and direct

subsidiary of Cardio (“ Otto ”) and Sudhir Srivastava Innovations Pvt.

Ltd., an Indian private limited company and indirect

subsidiary of Cardio (“ SSI ,” and together with Cardio and Otto, the “ SSI Parties ”) with respect

to a business combination between AVRA and the SSI Parties (the “ Transaction ”).

SSI, based in Haryana, India is engaged

in the development, commercialization, manufacturing and sale of medical and surgical robotic systems utilizing patents, trademarks and

other intellectual property held by Dr.

Sudhir (the “ SSI Intellectual Property ”).

If and when the transaction is consummated, the

business of the SSI Parties, including the SSI Intellectual Property will be owned by AVRA.

The shareholders of the SSI Parties will own

95 % of the common stock of post-transaction AVRA and the current shareholders of AVRA will own 5 % of the common stock of post-transaction

In addition, there will be changes in composition of the board of directors, implementation of corporate governance policies and

changes in management, all with a view to listing the common stock of AVRA on the Nasdaq Stock Market, LLC or another National Securities

In addition, AVRA will change its name to “ SS Innovations, Inc.

Consummation of the Transaction is subject to,

among other matters, the negotiation and execution of definitive agreements and documentation, containing, in addition to the above terms,

terms and conditions customary for agreements of this type and nature, including, without limitation, representations, warranties, and

indemnities of the parties.

Consummation of the Transaction is also subject

to completion of a due diligence review by each party of the other, the results of which shall be satisfactory to the reviewing parties

in their sole discretion.

Given the foregoing, there can be no assurance

given that the Company will be able to successfully complete the Transaction.

In connection with executing the letter of intent,

we advanced the SSI Parties, the amount of $ 2,250,000 (the “ Interim Financing ”).

The Interim Financing is evidenced

by four notes, one for $ 100,000 one for $ 1,000,000 , one for $ 500,000 , and one for $ 900,000 .

All are one-year Automatically Convertible Notes made in favor

of the Company by Cardio, Otto and Dr Sudhir, jointly and severally (the “ Cardio Notes ”).

Interest on the Cardio Notes

shall accrue at the rate of 7 % per annum, payable together with the principal amount at maturity.

The Cardio Notes have an original issue

discount of 10 %.

If the Cardio Notes are not repaid in full on or at maturity, they will automatically convert into a percentage equity

interest in Cardio determined by dividing the principal amount of and accrued interest on the Cardio Notes divided by $ 100 million.

Cardio Notes contains customary default provisions and other typical terms and conditions.

We may make additional advances to the SSI Parties

of up to an aggregate principal amount of $ 5,000,000 of Interim Financing, evidenced by additional Cardio Notes.

These Cardio Notes will

be substantially similar in form and substance to the first Cardio Notes, provided , however , that Cardio Notes issued in

excess of an aggregate principal amount of $ 2.000,000 , will have an original issue discount of 6 % as opposed to 10 %, and the valuation

for determining conversion will be $ 250 million as opposed to $ 100 million.

In order to fund the Interim Financing, the

Company offered and sold one-year convertible promissory notes (the “ Convertible Notes ”) of $1,000,000, and

$500,000 to one accredited investor and $100,000 and $900,000 to another.

The Convertible Notes will have the same interest rate and

payment terms as the Cardio Notes and otherwise be substantially similar to the Cardio Notes, provided , however , that

the Convertible Notes do not have an original issue discount.

Further, upon consummation of the Transaction (if and when it is

consummated) the Convertible Notes will automatically convert into a number of AVRA Shares determined by dividing the principal

amount of the Convertible Notes by $100 million and multiplying such number expressed as a percentage by the number of AVRA Shares

issued to Dr.

Sudhir and the other shareholders of the SSI Parties (if any) upon closing of the Transaction.

The Company may offer

and sell up to an aggregate principal amount of $5,000,000 in Convertible Notes in order to fund the Interim Financing.

The Convertible Notes were issued in a private

transaction pursuant to the exemptions from registration under the Section 4(a)2 of the Securities Act of 1933, as amended (the “ Securities

Act ”) and the rules and regulations promulgated thereunder.

During the three and

six months ended June 30, 2020, 37,500 warrants were valued at $ 51,740 and expensed as stock compensation.

NOTE 5 – INCOME TAXES

The Company’s deferred tax assets at September

The Company’s deferred tax assets at June

30, 2022 consist of net operating loss carry forwards of $ 8,475,145 .

Using a new federal statutory tax rate of 21 %, the valuation allowance

balance as of September 30, 2022, totals $ 0 .

balance as of June 30, 2021 total $ 0 .

Due to the uncertainty of their realization, no

2 unchanged sentences

The increase in the valuation allowance was the result of increases in the net operating losses discussed above.

the Company’s provision for income taxes is $- 0 - for the nine months ended September 30, 2022, and 2021.

At September 30, 2022 and December 31, 2021, the

Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required.

The Company does not

expect that its unrecognized tax benefits will materially increase within the next twelve months.

The Company recognizes interest and

penalties related to uncertain tax positions in general and administrative expense.

At September 30, 2021 and December 31, 2020, the Company

has not recorded any provisions for accrued interest and penalties related to uncertain tax positions.

The Company files U.S.

federal and state income

tax returns in jurisdictions with varying statutes of limitations.

the Company’s provision for income taxes is $ 0 for the six months ended June 30 ,

2022 and 2021.

June 30, 2021 and December 31, 2020, the Company had no material unrecognized tax benefits

and no adjustments to liabilities or operations were required.

The Company does not expect that its unrecognized tax benefits will materially

increase within the next twelve months.

The Company recognizes interest and penalties related to uncertain tax positions in general and

administrative expense.

At June 30, 2022 and December 31, 2021, the Company has not recorded

any provisions for accrued interest and penalties related to uncertain tax positions.

Company files U.S.

federal and state income tax returns in jurisdictions with varying statutes of limitations.

NOTE 6 – STOCKHOLDERS’ DEFICIT

13 unchanged sentences

● 128,300 shares of restricted common stock required to be issued, to six consultants and service providers for services rendered through September 30, 2018;

● 400 shares of restricted common stock required to be issued,

for services rendered through February 28, 2018;

On January 4, 2019, 115,050 Shares at a value of $ 1.25 per share were issued for service

On April 1, 2019, 95,050 shares at a value ranging

from $ 1.25 -$ 2.41 per share were issued for services rendered.

● 400 shares of restricted common stock required to be issued, for services rendered through February 28, 2018;

On January 4, 2019, 115,050 Shares at a value

of $ 1.25 per share were issued for service rendered.

On April 1, 2019, 95,050 shares at a value

ranging from $ 1.25 -$ 2.41 per share were issued for services rendered.

On July 1, 2019, 79,672 shares at a value ranging

6 unchanged sentences

42 -$ 2.79 per share were issued for services rendered.

During the first quarter 2021, 1,025,000 shares

at a value ranging from $ 0.89 -$ 1.07 per share were issued for services rendered.

During the first quarter 2021, 85,00 shares at

a value ranging from $ 0.89 -$ 1.07 per share were issued for services rendered.

During the second quarter 2021, 198,378 shares

at a value ranging from $ 0.89 -$ 1.02 per share were issued for services rendered.

During the third quarter 2021 several holders

of stock options elected to exercise their stock options with a cashless exercise provision resulting in the issuance of 543,375 shares

of common stock.

During third quarter 2021 several holders of stock

options elected to exercise their stock options with a cashless exercise provision resulting in the issuance of 543,375 shares of common

86,000 shares were also exercised through payments for their options.

On July 1, 2022 the Company issued

240,270 shares of common stock as payment in full for the accrued but unpaid fees due to its Counsel.

On July 1, 2022 the Company issued 27,250 shares

of common stock to its patent attorney per their fee agreement.

On July 1, 2022 the Company issued 160,000 shares

of common stock to its Chief Strategy Officer as required by his Stock Grant Award dated April 15, 2019 and his Employment Agreement dated

March 1, 2018.

On July 1, 2022 the Company issued 40,000 shares

of common stock to its Chief Medical Officer as required by his employment agreement dated September 15, 2020

On July 1, 2022 the Company issued a total of

569,747 shares of common stock to several consultants

are entitled to one vote for each share of common stock.

No preferred stock has been issued.

On July 1, 2022 the Company paid $ 5,000 and issued

to a consultant an option for 2,520,000 common shares with an exercise price of $ 0.10 per share as a performance bonus and for foregoing

all accrued and unpaid fees due for 2022 and for foregoing a portion of the fees due for the remaining five months of calendar year 2022.

The option vested immediately.

On July 25, 2022 the Directors and Shareholders

holding a majority of the issued and outstanding common shares of the Company adopted, by joint written consent, a resolution to increase

the Company’s common stock reserved for issuance under the Company’s 2016 Incentive Stock Plan to 20,000,000 .

In August 2022 the Company sold 1,000,000 shares

of common stock at a price of $ 0.25 per share receiving proceeds of $ 250,000 .

In the third quarter of 2022 the Company raised

$ 250,000 from one accredited investor through the sale of one million of the Company’s restricted common shares.

On June 16, 2022 the Company issued 240,270 shares

of common stock as payment in full for the accrued but unpaid legal fees due to Gutierrez Bergman Boulris PLLC.

NOTE 7 – 2016 INCENTIVE STOCK PLAN

On August 1, 2016, the Company adopted the 2016 Incentive

Stock Plan (the “Plan”).

The Plan provides for the granting of options to employees, directors, consultants and advisors to

purchase up to 3,000,000 shares of the Company’s common stock.

The Board is responsible for the administration of the Plan.

Board determines the term of each option, the option exercise price, the number of shares for which each option is granted and the rate

at which each option is exercisable.

On August 1, 2016, the Company adopted the 2016

Incentive Stock Plan (the “Plan”).

The Plan provides for the granting of options to employees, directors, consultants and

advisors to purchase up to 3,000,000 shares of the Company’s common stock.

The Board is responsible for administration of the Plan.

The Board determines the term of each option, the option exercise price, the number of shares for which each option is granted and the

rate at which each option is exercisable.

Incentive stock options may be granted to any officer or employee at an exercise price per share

1 unchanged sentence

On August 1, 2019, the Board increased the plan to 10,000,000

shares of common stock and in July 2022 increased the plan to 20,000,000 shares of common stock.

shares of common stock.

For options granted October 1, 2017, the following

3 unchanged sentences

of $ 1.25 per share.

For options granted July 1, 2018, the following factors

For options granted July 1, 2018, the following factors were used:

volatility 31.34 %;

expected term of 3 years, risk-free interest rate of 2.00 %, dividend yield of 0 % and exercise price of $ 1.25

For options granted May 1, 2018, the following factors

expected term of 3 years, risk-free interest rate of 2.00 %, dividend yield of 0 % and exercise price of $ 1.25 per share.

For options granted May 1, 2018, the following

factors were used:

volatility 62.16 %;

expected term of 3 years, risk-free interest rate of 2.00 %, dividend yield of 0 % and exercise price of $ 1.25

On July 1, 2018 options for 75,000 shares were issued

to our Counsel for services rendered totaling $ 21,000 .

expected term of 3 years, risk-free interest rate of 2.00 %, dividend yield of 0 % and exercise price

of $ 1.25 per share.

On July 1, 2018 options for 75,000 shares were

issued to our Counsel for services rendered totaling $ 21,000 .

These shares are vested immediately and expire on July 1, 2023 .

The exercise price

price is $ 1.25 .

For the year ended December 31, 2019 and 2018,

1 unchanged sentence

Non-vested Options for 97,639 shares were forfeited during March 2018.

On December 1, 2019, the Company granted to its majority

shareholder options to purchase 750,000 common shares of the Company at an exercise price per share will be $ 1.00 .

All shares will immediately

vest, and the Option will expire five years from the date of issuance.

On December 1, 2019, the Company granted to its

majority shareholder options to purchase 750,000 common shares of the Company at an exercise price per share will be $ 1.00 .

will immediately vest, and the Option will expire five years from the date of issuance.

At December 31, 2019 and 2018 options representing

2 unchanged sentences

from the issue date.

Except for the options for 8,930,000 shares issued to the CEO, to the Company’s counsel for 115,000 shares,

to the Company’s Chief Medical Officer for 500,000, to the Company’s Chief Strategy Officer for 500,000 shares and to a consultant

for 3,820,000 that vested immediately, all the options issued to date vest over three years.

Stock options are accounted for in accordance with

FASB ASC Topic 718, Compensation –Stock Compensation , with option expense amortized over the vesting period based on the

Black-Scholes option-pricing model fair value on the grant date, which includes a number of estimates that affect the amount of expense.

During the three months ended September 30, 2022 and

2021, $ 664,760 and $ 266,746 respectively, for stock based compensation.

During the nine months ended September 30, 2022 and 2021, $ 759,527

and $ 812,381 , respectively, of expensed stock options has been recorded as stock-based compensation on the Statement of Operations.

Except for the option for 1,750,000 shares issued to the CEO and to the Company’s counsel for 40,000 shares

that vested immediately, all the options issued to date vest over three years.

Stock options are accounted for in accordance

with FASB ASC Topic 718, Compensation –Stock Compensation , with option expense amortized over the vesting period based on

the Black-Scholes option-pricing model fair value on the grant date, which includes a number of estimates that affect the amount of expense.

During the three months ended June 30, 2022, and

2021, $ 28,396 and $ 326,035 respectively, of expensed stock options has been recorded as stock-based compensation.

the six months ended June 30, 2022, and 2021, $ 56,637 and $ 545,636 , respectively, of expensed stock options has been recorded as

stock-based compensation.

The total amount of unrecognized compensation cost related to non-vested options was $ 462,490 as of June 30,

This amount will be recognized over a period of 39 months expiring September 30, 2024 .

The grant date fair value of options granted during

the year of 2018 and 2019 were estimated on the grant date using the Black-Scholes model with the following assumptions:

For options granted May 1, 2018, the following factors

For options granted May 1, 2018, the following

factors were used;

volatility 62.16 %;

expected term of 3 years, risk-free interest rate of 2.00 %, dividend yield of 0 % and exercise price of $ 1.25

For options granted July 1, 2018, the following factors

expected term of 3 years, risk-free interest rate of 2.00 %, dividend yield of 0 % and exercise price

of $ 1.25 per share.

For options granted July 1, 2018, the following

factors were used;

volatility 31.34 %;

expected term of 3 years, risk-free interest rate of 2.00 %, dividend yield of 0 % and exercise price of $ 1.25

expected term of 3 years, risk-free interest rate of 2.00 %, dividend yield of 0 % and exercise price

of $ 1.25 per share.

For options granted February 1, 2019:

Volatility 50.58 %,

50.58 %, term 3 years, risk-free interest rate of 2.00 %, dividend yield of 0 % and exercise price of $ 2.00 per share.

For options granted April

Volatility 48.52 %, term 3 years, risk-free interest rate of 2.00 %, dividend yield of 0 % and exercise price of $ 1.25 per share.

For options granted

April 1, 2019:

Volatility 48.52 %, term 3 years, risk-free interest rate of 2.00 %, dividend yield of 0 % and exercise price of $ 1.25 per

For options granted August 1, 2019:

Volatility 62.43 %,

62.43 %, term 3 years, risk-free interest rate of 2.00 %, dividend yield of 0 % and exercise price of $ 2.00 per share.

For options granted October 1, 2019:

Volatility 48.57 %,

48.57 %, term 3 years, risk-free interest rate of 2.00 %, dividend yield of 0 % and exercise price of $ 2.00 per share.

For options granted December 1, 2019:

Volatility 61.91 %,

61.91 %, term 3 years, risk-free interest rate of 2.00 %, dividend yield of 0 % and exercise price of $ 1.00 per share.

3 unchanged sentences

value is $ 0.45 , exercise $ 0.25 , rate 2 %, and volatility 39.73 %.

On July 1, 2022 the Company issued to its CEO an option for 5,400,000 common

shares with an exercise price of $ 0.10 per share as a performance bonus and for foregoing all of his 2022 salary.

The option vested immediately.

On July 1, 2022 the Company issued to its Chief Medical

Officer an option for 500,000 common shares with an exercise price of $ 0.10 per share as a performance bonus.

The option vested immediately.

On July 1, 2022 the Company issued to its Chief Strategy

Advisor an option for 500,000 common shares with an exercise price of $ 0.10 per share as a performance bonus.

The option vested immediately

In July 2022, four investors exercised their put options

obtained from the Offering dated October 26, 2020, transferred their Membership Units in Avra Air LLC back to AVRA and received 301,027

shares of the Company’s common stock in return.

Option values are calculated using Black Scholes with

the following inputs:

For options granted June 1, 2022 the fair market

value is $ 0.13 , exercise $ 0.25 , rate 2 %, and volatility 67.92 %.

Option values are calculated using Black Scholes

with the following inputs:

expected volatilities are based on the average volatilities of six similar companies;

fair market values are calculated

using the implied share values of recent company financings or OTC closing prices for that day, whichever is more suitable;

rate used was 2 %.

fair market values are

calculated using the implied share values of recent company financings or OTC closing prices for that day, whichever is more suitable;

risk-free rate used was 2 %.

NOTE 8 – COMMITMENTS

Intellectual property

Effective May 1, 2016, the Company entered into a

Research Agreement (the “Research Agreement”) with the University of Central Florida (“UCF” or the “University”)

Effective May 1, 2016, the Company entered into

a Research Agreement (the “Research Agreement”) with the University of Central Florida (“UCF” or the “University”)

for the development of a prototype surgical robotic device supporting minimal invasive surgical facial corrections.

5 unchanged sentences

were required.

The Company agreed to extend funding of $ 163,307 from

AVRA’s existing funds.

The Company agreed to extend funding of $ 163,307

from AVRA’s existing funds.

In addition, AVRA paid $ 43,548 for outright ownership

11 unchanged sentences

of products using the intellectual property exceeds $ 20,000,000 .

Employment Agreements

On July 1, 2016, the Company entered into an Employment

7 unchanged sentences

fully vested on August 15, 2016.

On August 1, 2016, the Company entered into a one-year

Employment Agreement with its Chief Financial Officer.

On August 1, 2016, the Company entered into a

one-year Employment Agreement with its Chief Financial Officer.

The agreement provides for an annual salary of $108,000 per year.

Through December

2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of

Further the Agreement provides that the employee will receive a three-year option to purchase 210,000 shares of the Company’s

common stock at an exercise price of $0.10 per share, with 70,000 shares becoming fully vested upon each yearly anniversary.

are to be surrendered and cancelled if the Agreement is terminated.

The Agreement has expired but its compensation terms continue in effect

as long as the employee remains employed by the Company.

On August 1, 2016, the Company entered into a three-year

Employment Agreement with its Vice President of Global Business Development.

The agreement provides for an annual salary of $96,000 per

year, increasing to $144,000 per year beginning July 2017.

December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some

or all of his salary.

Further the Agreement provides that the employee will receive a three-year option to purchase 210,000 shares of

the Company’s common stock at an exercise price of $0.10 per share, with 70,000 shares becoming fully vested upon each yearly anniversary.

The options are to be surrendered and cancelled if the Agreement is terminated.

The Agreement has expired but its compensation terms continue

in effect as long as the employee remains employed by the Company.

On August 1, 2016, the Company entered into a

three-year Employment Agreement with its Vice President of Global Business Development.

The agreement provides for an annual salary of

$96,000 per year, increasing to $144,000 per year beginning July 2017.

Through December 2016, the employee agreed to not receive the compensation

3 unchanged sentences

with 100,000 shares vested on each yearly anniversary.

Further, on July 1, 2016, the Company entered into

Indemnification Agreements with the Chairman and Chief Executive Officer, and on August 1, 2016 the Chief Financial Officer and the Vice-President

of Global Business Development providing for the Company to indemnify the individuals for all expenses, judgments, etc.

incurred while

serving in various capacities with the Company.

Commencing March 1, 2018, the Company entered into

an employment agreement with its new Chief Strategy Officer whereby compensation will be determined upon sufficient funding of the Company.

The Company granted a 300,000 share stock award under its 2016 Incentive Stock Plan, which vests in five equal annual installments of

60,000 shares each.

In addition, on May 1, 2018 options for 250,000 shares

that vest monthly over 3 years were also issued to our Chief Strategy Officer.

Further, on July 1, 2016, the Company entered

into Indemnification Agreements with the Chairman and Chief Executive Officer, and on August 1, 2016 the Chief Financial Officer and the

Vice-President of Global Business Development providing for the Company to indemnify the individuals for all expenses, judgments, etc.

incurred while serving in various capacities with the Company.

Commencing March 1, 2018, the Company entered

into an employment agreement with its new Chief Strategy Officer whereby compensation will be determined upon sufficient funding of the

The Company granted a 300,000 share stock award under its 2016 Incentive Stock Plan, which vests in five equal annual installments

of 60,000 shares each.

In addition, on May 1, 2018 options for 250,000

shares that vest monthly over 3 years were also issued to our Chief Strategy Officer.

These options expire on May 1, 2023 and are exercisable

Commencing January 1, 2019, the Company entered into

a consulting agreement with an IR/PR Company whereby compensation will be $ 1,500 per month for six months.

Commencing January 1, 2019, the Company entered

into a consulting agreement with an IR/PR Company whereby compensation will be $ 1,500 per month for six months.

During third quarter 2019,

15 unchanged sentences

1,000,000 shares were fully vested on July 1, 2020.

The Company occupies office and laboratory space in

Orlando, Florida under a lease agreement that expired on July 31, 2018 .

The Company occupies office and laboratory space

in Orlando, Florida under a lease agreement that expired on July 31, 2018 .

Effective August 1, 2018 and expiring July 31, 2019 , the Company

6 unchanged sentences

Company pay insurance, maintenance and taxes with a monthly lease expense of $ 1,474.17 plus applicable sales tax.

Effective January

1, 2021, the Company signed an amendment which modified the August 1, 2020 agreement, increasing the monthly lease expense to $ 1,964.74 plus

applicable sales tax.

Either party may cancel the agreement at any time with 30 days’ notice.

January 1, 2021, the Company signed an amendment which modified the August 1, 2020 agreement, increasing the monthly lease expense to

$ 1,964.74 plus applicable sales tax.

Either party may cancel the agreement at any time

with 30 days’ notice.

NOTE 9 – OTHER MATTERS

13 unchanged sentences

condition, or liquidity for fiscal year 2020.

On March 27, 2020, President Trump signed into law

the “Coronavirus Aid, Relief, and Economic Security (CARES) Act.” The CARES act was enacted as a response to the COVID-19

outbreak discussed above and is meant to provide companies with economic relief.

The CARES Act, among other things, includes

provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback

periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified

charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property.

On March 27, 2020, President Trump signed into

law the “Coronavirus Aid, Relief, and Economic Security (CARES) Act.” The CARES act was enacted as a response to the

COVID-19 outbreak discussed above and is meant to provide companies with economic relief.

The CARES Act, among other things,

includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss

carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations

on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property.

NOTE 10 – SUBSEQUENT EVENTS

From October 2022 through the date of this filling,

The Company has evaluated subsequent events through

the date that the financial statements were issued and determined that there were subsequent events requiring adjustments to or disclosure

in the financial statements.

On July 1, 2022 the Company paid $ 5,000 and issued

to a consultant an option for 2,520,000 common shares with an exercise price of $ 0.10 per share as a performance bonus and for foregoing

all accrued and unpaid fees due for 2022 and for foregoing a portion of the fees due for the remaining five months of calendar year 2022.

The option vested immediately.

On July 1, 2022 the Company issued to its CEO an option for 5,400,000

common shares with an exercise price of $ 0.10 per share as a performance bonus and for foregoing all of his 2022 salary.

The option vested

On July 1, 2022 the Company issued to its Chief

Medical Officer an option for 500,000 common shares with an exercise price of $ 0.10 per share as a performance bonus.

The option vested

On July 1, 2022 the Company issued to its Chief

Strategy Advisor an option for 500,000 common shares with an exercise price of $ 0.10 per share as a performance bonus.

The option vested

On July 1, 2022 the Company issued 240,270 shares

of common stock as payment in full for the accrued but unpaid fees due to its Counsel.

On July 1, 2022 the Company issued 27,250 shares

of common stock to its patent attorney per their fee agreement.

On July 1, 2022 the Company issued 160,000 shares

of common stock to its Chief Strategy Officer as required by his Stock Grant Award dated April 15, 2019 and his Employment Agreement dated

March 1, 2018.

On July 1, 2022 the Company issued 40,000 shares

of common stock to its Chief Medical Officer as required by his employment agreement dated September 15, 2020

On July 1, 2022 the Company issued a total of

569,747 shares of common stock to several consultants.

In July 2022, four investors exercised their put

options obtained from the Offering dated October 26, 2020, transferred their Membership Units in Avra Air LLC back to AVRA and received

301,027 shares of the Company’s common stock in return.

On July 25, 2022 the Directors and Shareholders

holding a majority of the issued and outstanding common shares of the Company adopted, by joint written consent, a resolution to increase

the Company’s common stock reserved for issuance under the Company’s 2016 Incentive Stock Plan to 20,000,000 .

On August 5, 2022, AVRA entered into a non-binding

letter of intent with Dr.

Sudhir Srivastava (“ Dr.

Srivastava ”), Cardio Ventures Pvt.

Ltd., a Bahamian private limited

company of which Dr.

Srivastava is the sole stockholder(“ Cardio ”), Otto Pvt, Ltd., a Bahamian private limited company

and direct subsidiary of Cardio (“ Otto ”) and Sudhir Srivastava Innovations Pvt.

Ltd., an Indian private limited company

and indirect subsidiary of Cardio (“ SSI ,” and together with Cardio and Otto, the “ SSI Parties ”)

with respect to a business combination between AVRA and the SSI Parties (the “ Transaction ”).

SSI, based in Haryana,

India is engaged in the development, commercialization, manufacturing and sale of medical and surgical robotic systems utilizing patents,

trademarks and other intellectual property held by Dr.

Srivastava (the “ SSI Intellectual Property ”).

If and when the transaction is consummated, the

business of the SSI Parties, including the SSI Intellectual Property will be owned by AVRA.

The shareholders of the SSI Parties will own

95 % of the common stock of post-transaction AVRA and the current shareholders of AVRA will own 5 % of the common stock of post-transaction

In addition, there will be changes in composition of the board of directors, implementation of corporate governance policies and

changes in management, all with a view to listing the common stock of AVRA on the Nasdaq Stock Market, LLC or another National Securities

In addition, AVRA will change its name to “ SS Innovations, Inc.

Consummation of the Transaction is subject to,

among other matters, the negotiation and execution of definitive agreements and documentation, containing, in addition to the above terms,

terms and conditions customary for agreements of this type and nature, including, without limitation, representations, warranties, and

indemnities of the parties.

Consummation of the Transaction is also subject

to completion of a due diligence review by each party of the other, the results of which shall be satisfactory to the reviewing parties

in their sole discretion.

Given the foregoing, there can be no assurance

given that the Company will be able to successfully complete the Transaction.

In connection with executing the letter of

intent, we advanced the SSI Parties, the amount of $ 2,250,000 (the “ Interim Financing ”).

The Interim Financing is

evidenced by four notes, one for $ 100,000 , one for $ 1,000,000 , one for $ 500,000 , and one for $ 900,000 .

All are one-year

Automatically Convertible Notes made in favor of the Company by Cardio, Otto and Dr Srivastava, jointly and severally (the

“ Cardio Notes ”).

Interest on the Cardio Notes shall accrue at the rate of 7 % per annum, payable together with the

principal amount at maturity.

The Cardio Notes have an original issue discount of 10 %.

If the Cardio Notes are not repaid in full on

or at maturity, they will automatically convert into a percentage equity interest in Cardio determined by dividing the principal

amount of and accrued interest on the Cardio Notes divided by $ 100 million.

The Cardio Notes contains customary default provisions

and other typical terms and conditions.

We may make additional advances to the SSI Parties

of up to an aggregate principal amount of $ 5,000,000 of Interim Financing, evidenced by additional Cardio Notes.

These Cardio Notes will

be substantially similar in form and substance to the first Cardio Notes, provided , however , that Cardio Notes issued in

excess of an aggregate principal amount of $2.000, 000 , will have an original issue discount of 6 % as opposed to 10 %, and the valuation

for determining conversion will be $ 250 million as opposed to $ 100 million.

In order to fund the Interim Financing, the Company

offered and sold one-year convertible promissory notes (the “ Convertible Notes ”) of $1,000,000, and $500,000 to one

accredited investor and $100,000 and $900,000 to another.

The Convertible Notes will have the same interest rate and payment terms as

the Cardio Notes and otherwise be substantially similar to the Cardio Notes, provided , however , that the Convertible Notes

do not have an original issue discount.

Further, upon consummation of the Transaction (if and when it is consummated) the Convertible

Notes will automatically convert into a number of AVRA Shares determined by dividing the principal amount of the Convertible Notes by

$100 million and multiplying such number expressed as a percentage by the number of AVRA Shares issued to Dr.

Srivastava and the other

shareholders of the SSI Parties (if any) upon closing of the Transaction.

The Company may offer and sell up to an aggregate principal

amount of $5,000,000 in Convertible Notes in order to fund the Interim Financing.

The Convertible Notes were issued in a private

transaction pursuant to the exemptions from registration under the Section 4(a)2 of the Securities Act of 1933, as amended (the “ Securities

Act ”) and the rules and regulations promulgated thereunder.

In August 2022 the Company sold 1,000,000 shares

of common stock at a price of $ 0.25 per share receiving proceeds of $ 250,000 .

On September 7 th 2022, Avra Air LLC

purchased back the 49.8 % voting rights held by the Company in return for all rights to any royalty fees which would have previously been

owed by the Company to Avra Air LLC and $ 26,000 paid via the transfer of 52,000 restricted Company shares owned.

From September 2022 through the date of this filling,

the Company has sold 2,261,000 shares of common stock at a price of $ 0.25 per share receiving proceeds of $ 565,250 .

On November 7, 2022, AVRA

entered into a definitive Merger Agreement (the “ Merger Agreement ”), by and among AVRA, AVRA-SSI Merger Corporation,

a Delaware corporation and wholly-owned subsidiary of AVRA (“ Merger Sub ”), Cardio Ventures, Inc., a Delaware corporation

On November 7, 2022,

AVRA entered into a definitive Merger Agreement (the “ Merger Agreement ”), by and among AVRA, AVRA-SSI Merger Corporation,

a Delaware corporation and wholly owned subsidiary of AVRA (“ Merger Sub ”), CardioVentures, Inc., a Delaware corporation

(“ SSI - DE ”) Dr.

8 unchanged sentences

Srivastava (the “ SSI Intellectual Property ”).

Pursuant to the Merger Agreement,

Merger Sub will merge with and into SSI – DE (the “ Merger ”).

In the Merger, holders of the outstanding shares

of common stock of SSI – DE at closing (including certain parties providing Interim Financing as described below), will receive

Pursuant to the Merger

Agreement, Merger Sub will merge with and into SSI – DE (the “ Merger ”).

In the Merger, holders of the outstanding

shares of common stock of SSI – DE at closing (including certain parties providing Interim Financing as described below), will receive

in exchange for their SSI – DE shares, such number of shares of AVRA common stock as will result in such holders owning 95 % of the

4 unchanged sentences

Series A Non-Convertible Preferred Stock (the “ Series A Preferred Shares ”).

The Series A Preferred Shares

will vote together with Shares of our common stock as a single class on all matters presented to a vote of stockholders, except as required

by law and entitle the holders of the Series A Preferred Shares to exercise 51.0 % of the total voting power of the Company.

A Preferred Shares are not convertible into common stock, do not have any dividend rights and have a nominal liquidation preference.

Series A Preferred Shares also have certain protective provisions, such as requiring the vote of a majority of Series A Preferred Shares

to change or amend their rights, powers, privileges, limitations and restrictions.

The Series A Preferred Shares are automatically redeemable

by the Company for nominal consideration at such time as the holder owns less than 50 % of the shares of AVRA common stock received in

The Series A Preferred

Shares will vote together with Shares of our common stock as a single class on all matters presented to a vote of stockholders, except

as required by law and entitle the holders of the Series A Preferred Shares to exercise 51.0 % of the total voting power of the Company.

The Series A Preferred Shares are not convertible into common stock, do not have any dividend rights and have a nominal liquidation preference.

The Series A Preferred Shares also have certain protective provisions, such as requiring the vote of a majority of Series A Preferred

Shares to change or amend their rights, powers, privileges, limitations and restrictions.

The Series A Preferred Shares are automatically

redeemable by the Company for nominal consideration at such time as the holder owns less than 50 % of the shares of AVRA common stock received

in the Merger.

Concurrent with consummation

14 unchanged sentences

● AVRA shall have increased its authorized common stock to 250,000,000 shares.

The Merger Agreement, the

Merger and the above corporate actions have been approved by AVRA’s board of directors and majority stockholders.

The Merger Agreement,

the Merger and the above corporate actions have been approved by AVRA’s board of directors and majority stockholders.

They are subject

2 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1. Financial Statements